OmniAb (OABI) Reiterated at Buy by Stifel: FY26 Catalysts Increasingly Actionable

Stifel analyst Stephen Willey reiterated a Buy rating and $9.00 price target on OmniAb, Inc. (NASDAQ: OABI).

The analyst commented, " We’re reiterating our Buy-rated thesis following management’s earnings announcement and corporate update. We believe y/y growth in FY25 active partners/programs (+17/12%) reflects an increasingly encouraging pharma/biotech R&D spending environment which should remain a FY26 tailwind. We believe the calendar of FY26 clinical/regulatory catalysts for the 32 active clinical/approved assets appears increasingly actionable – and would highlight 1) 1H26/2H26 topline P1/2 data for TEV-‘408 (TEVA’s IL-15-targeting mAb which just received $500M in RPRX-derived funding to accelerate clinical development) in vitiligo/celiac disease; 2) 1H26 topline P3 data for IMVT’s batoclimab in TED; and 3) 2H26 topline P3/ P2 data for IMVT-1402 in ACPA+ RA/cutaneous LE. And we believe the FY27 catalyst calendar – highlighted by potential topline IMVT-1402 registrational data across multiple indications (GD/MG/CIDP) – will prove to be even more important for investors. Continued OpEx discipline coupled w/ improving visibility into partnerderived milestones/royalites and xPloration-mediated optionality creates a seemingly clearer path to sustainable profitability."

For an analyst ratings summary and ratings history on OmniAb, Inc. click here. For more ratings news on OmniAb, Inc. click here.

Shares of OmniAb, Inc. closed at $1.81 yesterday.

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Deere (DE) PT Lowered to $570 at JPMorgan Ahead of Earnings